Abstracts Only
SSAT residents Corner
Find SSAT on Facebook SSAT YouTube Channel Follow SSAT on Twitter
Back to 2006 Program and Abstracts
Short Tandem Repeat Polymorphism In EXON 4 Of Esophageal Cancer Related Gene - 2 As A Prognostic Marker For Esophageal Carcinoma
Tamina Rawnaq1, Jussuf T. Kaifi1, Paulus G. Schurr1, Michael Bubenheim2, Oliver Mann1, Emre F. Yekebas1, Petra Merkert1, Viacheslav Kalinin1, Bjoern-Christian Link1, Tim Strate1, Guido Sauter3, Klaus Pantel4, Jakob R. Izbicki1; 1Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Institute for Biometry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 4Institute for Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Short tandem repeat (STR) polymorphisms in exon 4 of esophageal cancer related gene (ECRG2) have been described to be a risk marker for esophageal carcinoma. The aim of the present study was to examine whether ECRG2 STR polymorphisms are a genetic prognostic marker for esophageal carcinoma. 86 esophageal carcinoma patients that underwent complete surgical resection were included. We retrospectively analyzed peripheral blood samples for STR TCA3/TCA3, TCA3/TCA4 and TCA4/TCA4 in the noncoding region of exon 4 of ECRG2 by using PCR, capillary electrophoresis and DNA sequencing analysis. Associations between STRs and survival were investigated with log-rank test and Cox multivariable analysis. All statistical tests were two-sided. ECRG2 STR TCA3/TCA3 and TCA3/TCA4 genotype were found in 40 (47%) patients respectively, and TCA4/TCA4 was found in 6 (7%) cases. TCA3/TCA3 was statistically significantly associated with reduced tumor-specific, relapse-free and overall survival, compared with grouped TCA3/TCA4 and TCA4/TCA4 genotypes (P<0.05; log-rank test). The median tumor-specific survival of patients with TCA3/TCA3 genotype was 19 months (95% confidence interval [CI] 5 - 33 months) and TCA3/TCA4 and TCA4/TCA4 genotype was 34 months (95% CI: 12 - 55 months). TCA3/TCA3 STR in ECRG2 was statistically the strongest prognostic factor for tumor-specific (relative risk [RR] 2.34 (95% CI 1.31-4.16); p=0.004) and relapse-free survival (RR 2.89, 95% CI 1.63 - 5.11; p<0.001) determined by multivariable Cox regression analysis. STR polymorphism TCA3/TCA3 in exon 4 of ECRG2 is associated with poor clinical outcome in esophageal cancer patients. ECRG2 might play a role in carcinogenesis of esophageal carcinoma and the mechanism has to be explored in future studies.


Back to 2006 Program and Abstracts
Quick Links
About the SSAT
Membership
Pay Membership Dues
Meetings & Education
Awards
Foundation
Publications
Advocacy
Donate Today